Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jawed Fareed

Showing results (291-300 of 393) with videos related to

Pageof 40
Sort By:
Journal of Pharmacy Practice|July 16, 2020
Impact of Pulmonary Embolism Response Team on Anticoagulation Prescribing Patterns in Patients With Acute Pulmonary EmbolismShannon Kuhrau, Dalila Masic, Erin Mancl, et al.
Carbohydrate Polymers|April 7, 2023
Absolute pharmacokinetics of heparin in primatesYuefan Song, Ahmed Kouta, Lee M Cera, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 10, 2021
Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array ProfilingEmily Bontekoe, Yevgeniy Brailovsky, Debra Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 21, 2017
Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical PatientsLauren Shih, Nil Guler, Daneyal Syed, et al.
Thrombosis Research|February 28, 2004
Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primatesQing Ma, Christopher Schultz, Brian Neville, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 8, 2022
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic AnalysisSiddharth Mehrotra, Debra Hoppensteadt, Walter Jeske, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 10, 2008
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded productsJawed Fareed, Rodger L Bick, Gundu Rao, et al.
Thrombosis Research|April 18, 2002
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgGBrian Untch, Sarfraz Ahmad, Walter P Jeske, et al.
Journal of the American College of Cardiology|February 11, 2003
The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administrationJonathan D Marmur, Sunil X Anand, Ramanjit S Bagga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 18, 2021
Regulation of Cortisol in Patients Undergoing Total Joint ArthoplastyRajan Khanna, Hannah Slovacek, Jeffrey Liles, et al.
Pageof 40

Showing results (291-300 of 393) with videos related to

Sort By:
Pageof 40
Journal of Pharmacy Practice|July 16, 2020
Impact of Pulmonary Embolism Response Team on Anticoagulation Prescribing Patterns in Patients With Acute Pulmonary EmbolismShannon Kuhrau, Dalila Masic, Erin Mancl, et al.
Carbohydrate Polymers|April 7, 2023
Absolute pharmacokinetics of heparin in primatesYuefan Song, Ahmed Kouta, Lee M Cera, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 10, 2021
Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array ProfilingEmily Bontekoe, Yevgeniy Brailovsky, Debra Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 21, 2017
Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical PatientsLauren Shih, Nil Guler, Daneyal Syed, et al.
Thrombosis Research|February 28, 2004
Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primatesQing Ma, Christopher Schultz, Brian Neville, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 8, 2022
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic AnalysisSiddharth Mehrotra, Debra Hoppensteadt, Walter Jeske, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 10, 2008
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded productsJawed Fareed, Rodger L Bick, Gundu Rao, et al.
Thrombosis Research|April 18, 2002
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgGBrian Untch, Sarfraz Ahmad, Walter P Jeske, et al.
Journal of the American College of Cardiology|February 11, 2003
The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administrationJonathan D Marmur, Sunil X Anand, Ramanjit S Bagga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 18, 2021
Regulation of Cortisol in Patients Undergoing Total Joint ArthoplastyRajan Khanna, Hannah Slovacek, Jeffrey Liles, et al.
Pageof 40